Physician profile
Parmod Jindal
NPI 1740259191
$4,313.33
in general payments reported to CMS, 2019-2025
30 companies · $764 in 2025
The $764 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $429 · 2021: $821 · 2022: $637 · 2023: $581 · 2024: $642 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,987.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $432.57 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $364.95 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $357.00 | 2021-2025 | |
| Novo Nordisk INC | $349.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.96 | 2019-2025 | Jardiance |
| Amgen INC. | $261.30 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $246.44 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $212.79 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $198.06 | 2019-2022 | |
| Astellas Pharma US INC | $190.14 | 2019-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $157.45 | 2020-2025 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $152.99 | 2019-2023 | Trintellix |
| Aimmune Therapeutics, INC. | $150.57 | 2024-2025 | Zenpep, Vowst |
| Merck Sharp & Dohme LLC | $142.40 | 2019-2023 | Verquvo, Steglatro |
| Sumitomo Pharma America, INC. | $109.93 | 2023-2025 | Gemtesa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $93.28 | 2022-2025 | |
| Amarin Pharma, INC. | $85.36 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $67.61 | 2020-2025 | Austedo Xr, Austedo Xr |
| Dexcom, INC. | $59.88 | 2022-2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $56.81 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.42 | 2023-2024 | Xifaxan |
| Abbott Laboratories | $48.51 | 2019 | |
| Antares Pharma, INC. | $45.52 | 2024-2025 | Xyosted |
| Biohaven Pharmaceutical Holding Company LTD. | $41.41 | 2022 | |
| Sanofi-Aventis U.S. LLC | $33.56 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $31.53 | 2021 | |
| Nestle Healthcare Nutrition INC. | $20.66 | 2023 | |
| Sunovion Pharmaceuticals INC. | $19.70 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.69 | 2024 | Quviviq |
| Allergan, INC. | $14.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parmod Jindal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.